Clinical Trial Search

Primary: Incidence of Post-baseline Newly Occurring or Worsening PCS (Potentially Clinically Significant) Clinical Chemistry Values — 0; 1; 0; 0 Count of Participants

Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period

Primary: Severe Hypoglycemia Rescue — 127; 123 Participants

Primary: Progression Free Survival of Patients With Unresectable Angiosarcoma — 4.2; 4.3; 3.5; 2.9 months

Primary: Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24 — 72.09; 113.21 mL — p=<0.001

Primary: Change From Study Baseline in the Daily Normalized Daytime Average Number of Urinary Incontinence Episodes in Treatment Cycle 1 — 2.66; 2.97; 3.99; -1.19 urinary…

Primary: Tear Evaporation Rate — 77.7; 67; 75.3 g/m^2*h

Primary: Primary Efficacy Outcome Measure — 50; 49; 8 Participants — p=<0.0001

Primary: Percentage of Participants With Progression-free Survival (PFS) — 47.7; 44.1; 45.0 percentage of participants — p=0.60

Primary: Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts — -48.25; -52.72; -45.03 Percent change in inflammatory lesions

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 105; 101 Participants

Primary: Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects — 329.76; 334.98; 334.98; 401.21 titers

Primary: Self-reported Pain Scores Using 100m Visual Analog Scale 0-100 Pain Score. — 6.4; 12.3 mm

Primary: The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 8 Weeks. — 29; 27; 29 Participants — p=0.9601

Primary: Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis…